X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rifaximin-α (6) 6
hepatic encephalopathy (4) 4
cirrhosis (3) 3
rifaximin-alpha (3) 3
antidepressants (2) 2
diastolic drugs (2) 2
diseases of the digestive system. gastroenterology (2) 2
female (2) 2
gastroenterology & hepatology (2) 2
guidelines (2) 2
health economics (2) 2
humans (2) 2
ibs (2) 2
ibs treatment (2) 2
index medicus (2) 2
irritable bowel syndrome (2) 2
loperamide (2) 2
macrogols (2) 2
male (2) 2
quality of life (2) 2
recommendations (2) 2
rifaximin (2) 2
rifaximin α (2) 2
accidents (1) 1
adult (1) 1
aged (1) 1
anti-inflammatory agents, non-steroidal - pharmacokinetics (1) 1
anti-inflammatory agents, non-steroidal - pharmacology (1) 1
anti-inflammatory drugs (1) 1
antibacterial therapy (1) 1
approaches to therapy (1) 1
burden (1) 1
cell line (1) 1
classification (1) 1
colitis (1) 1
colon - cytology (1) 1
colon - drug effects (1) 1
colon - metabolism (1) 1
colon epithelial cells (1) 1
cost savings (1) 1
covert hepatic encephalopathy (1) 1
critical flicker frequency (1) 1
cytochrome p-450 (1) 1
cytochromes p450 (1) 1
detoxification system (1) 1
diagnosis (1) 1
diagnostics (1) 1
dietary fiber (1) 1
digestive system (1) 1
digestive system diseases (1) 1
disease management (1) 1
diverticular disease of the large intestine (1) 1
double-blind (1) 1
driving ability (1) 1
drug costs (1) 1
drug-metabolism (1) 1
efficacy (1) 1
encephalopathy (1) 1
end-stage liver disease (1) 1
ethanol (1) 1
etiology (1) 1
forms of the disease (1) 1
gastroenterology (1) 1
gastrointestinal diseases (1) 1
gene-expression (1) 1
health care costs (1) 1
health resources - utilization (1) 1
healthcare utilization (1) 1
hep g2 cells (1) 1
hepatic encephalopathy - drug therapy (1) 1
hepatology (1) 1
hospitalisation (1) 1
hospitals (1) 1
impact (1) 1
inactivation, metabolic - physiology (1) 1
inflammatory bowel diseases (1) 1
inflammatory-bowel-disease (1) 1
inhibition (1) 1
intestinal mucosa - cytology (1) 1
intestinal mucosa - drug effects (1) 1
intestinal mucosa - metabolism (1) 1
length of stay - statistics & numerical data (1) 1
liver cirrhosis (1) 1
liver cirrhosis - complications (1) 1
liver disease (1) 1
liver-cirrhosis (1) 1
medicine (1) 1
mesalazine (1) 1
metaanalysis (1) 1
metabolism (1) 1
microflora (1) 1
middle aged (1) 1
mortality (1) 1
multivariate analysis (1) 1
nf-kappa-b (1) 1
original research (1) 1
patient-reported outcomes (1) 1
patients (1) 1
pharmacology & pharmacy (1) 1
plus lactulose (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Przeglad Gastroenterologiczny, ISSN 1895-5770, 2018, Volume 13, Issue 4, pp. 259 - 288
In memory of Professor Witold Bartnik These guidelines constitute an update of the previous „Recommendations on the management of irritable bowel syndrome”... 
Recommendations | Rifaximin α | Loperamide | Antidepressants | IBS treatment | Diastolic drugs | Irritable bowel syndrome | IBS | Macrogols | Guidelines | irritable bowel syndrome | loperamide | macrogols | guidelines | diastolic drugs | antidepressants | recommendations | rifaximin
Journal Article
Przeglad gastroenterologiczny, ISSN 1895-5770, 2018, Volume 13, Issue 4, pp. 259 - 288
These guidelines constitute an update of the previous "Recommendations on the management of irritable bowel syndrome" issued in 2008. They have been developed... 
Irritable bowel syndrome | Disease management | Guidelines | irritable bowel syndrome | IBS treatment | rifaximin α | loperamide | macrogols | guidelines | diastolic drugs | antidepressants | IBS | Special Paper | recommendations
Journal Article
Journal Article
Therapeutic Advances in Gastroenterology, ISSN 1756-283X, 06/2019, Volume 12, p. 1756284819858256
textabstractBackground: After 5 years since the registration of rifaximin-α as a secondary prophylaxis for overt hepatic encephalopathy (HE) in the... 
end-stage liver disease | healthcare utilization | rifaximin-α | safety | efficacy | hepatic encephalopathy | PLUS LACTULOSE | IMPACT | METAANALYSIS | rifaximin-alpha | DOUBLE-BLIND | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Медицинский совет, ISSN 2079-701X, 12/2016, Issue 14, pp. 88 - 95
The article is devoted to one of the current issues of the internal medicine – to issues of diagnostics and therapeutic correction of the excessive bacterial... 
diagnostics | “excessive bacterial growth syndrome” in small intestine (ebgs) | rifaximin-α (alfa normix®) | therapeutic and preventive measures | antibacterial therapy | microflora
Journal Article
Медицинский совет, ISSN 2079-701X, 11/2017, Issue 15, pp. 68 - 75
The article is devoted to the classification and treatment of diverticular disease of the colon, which is by its prevalence, nature, clinical manifestations,... 
mesalazine | psyllium | diverticular disease of the large intestine (colon) | forms of the disease | classification | approaches to therapy | rifaximin-α (alfa normix) | dietary fiber
Journal Article
Hepatology, medicine and policy, ISSN 2059-5166, 2018, Volume 3, Issue 1, pp. 4 - 8
Hepatic encephalopathy (HE) is one of the most important severe complications of liver cirrhosis. Thought to be caused by elevated blood levels of gut-derived... 
Cirrhosis | Health economics | Patient-reported outcomes | Hepatic encephalopathy | Liver disease | Hospitalisation
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.